image: Copenhagen, March, 2025 - The University of Copenhagen is excited to announce TruDiagnostic, a leader in epigenetic testing, will present its latest advancements at the 12th Aging Research and Drug Discovery (ARDD) Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online. Ryan Smith, Founder and Global Head of Research and Development of TruDiagnostic, will speak on the transformative potential of DNA methylation in aging and disease risk prediction.
Credit: Aging Research and Drug Discovery
Copenhagen, March, 2025 - The University of Copenhagen is excited to announce TruDiagnostic, a leader in epigenetic testing, will present its latest advancements at the 12th Aging Research and Drug Discovery (ARDD) Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online. Ryan Smith, Founder and Global Head of Research and Development of TruDiagnostic, will speak on the transformative potential of DNA methylation in aging and disease risk prediction.
A Leap Towards Accessible Precision Medicine
At ARDD 2024, TruDiagnostic shared its first public data on Epigenetic Biomarker Proxies (EBPs). Since then, in collaboration with Dr. Jessica-Lasky Su’s team from Harvard, TruDiagnostic has published these unique algorithms, which provide a transformative technology to measure biological function, predict disease, and quantify multi-omics using just a few drops of blood. This milestone marks a paradigm shift in healthcare, combining accessibility, affordability, and enhanced diagnostic accuracy.
TruDiagnostic has developed over 1,700 EBPs that serve as proxies for clinical lab results, metabolomic, and proteomic measurements. Validation efforts show that, on average EBPs, outperform traditional biomarkers, offering:
-
62% greater accuracy in disease prediction than traditional lab work.
-
64% improved effectiveness in disease diagnosis than traditional lab work.
-
Comprehensive longitudinal insights, reflecting broader biological signals akin to HbA1c in chronic disease management.
New Diagnostic Approach More Accurate & Predictive Than Traditional Blood Testing
This year at ARDD 2025, TruDiagnostic is excited to share more novel research. Leveraging the EBPs, TruDiagnostic has developed Methylation Risk Scores (MRS)—an epigenetic measure of disease risk. Using hazard ratios and odds ratios, MRS assesses an individual’s likelihood of developing or already having a disease. Unlike static genetic tests, MRS reflects modifiable health risks, making it a powerful tool for early detection and preventive care.
Conference and Speaker Details
Ryan’s talk will introduce MRS and their performance in predicting health outcomes. He will specifically discuss their application in assessing the risk for conditions such as:
-
Chronic kidney disease (CKD)
-
Depression
-
Chronic liver disease
-
COPD
-
Cardiovascular disease
-
Stroke
-
Congestive heart failure
Additionally, he will explore their relevance in neurodegenerative diseases, including:
-
Alzheimer’s
-
Parkinson’s
-
Lewy body dementia
-
Vascular dementia
His presentation will highlight how these scores provide valuable insights into disease risk and progression. In addition, Ryan will share how the EBPs have been validated in numerous clinical studies and will showcase unique findings uncovered in PTSD, diet and nutrition, and more.
12th Aging Research & Drug Discovery Meeting
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
ardd@pharma.ai
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.
About TruDiagnostic
TruDiagnostic is a leading epigenetics company specializing in methylation-based testing for health and longevity. Leveraging the world’s largest private DNA methylation database, TruDiagnostic provides cutting-edge insights into aging, disease risk, and personalized health optimization.
Follow TruDiagnostic for epigenetic insights:
Instagram: @TruDiagnosticOfficial
Facebook & TikTok: @TruDiagnostic
Media Contact:
press@trudiagnostic.com